Correction to: Continous or fixedcarfilzomib, lenalidomide and dexamethasone (krd) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life surveyfrom European myeloma network (emn) Italy (Annals of Hematology, (2025), 104, 10, (5223-5236), 10.1007/s00277-025-06602-9)
Jiang B., Li J., Liu L., Du X., Jiang H., Hu J., Zeng X., Sakatani T., Kosako M., Deng Y., Ivanov V., Bondarenko S., Lee L.W.L., Khuhapinant A., Martynova E., Hasabou N., An J.J.H., Wang J. Correction to: Continous or fixedcarfilzomib, lenalidomide and dexamethasone (krd) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life surveyfrom European myeloma network (emn) Italy (Annals of Hematology, (2025), 104, 10, (5223-5236), 10.1007/s00277-025-06602-9). Annals of Hematology Vol.105 No.3 (2026). doi:10.1007/s00277-026-06880-x Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/115166
Title
Correction to: Continous or fixedcarfilzomib, lenalidomide and dexamethasone (krd) for relapsed-refractory multiple myeloma: long-term follow-up from a multicenter, retrospective real-life surveyfrom European myeloma network (emn) Italy (Annals of Hematology, (2025), 104, 10, (5223-5236), 10.1007/s00277-025-06602-9)
In the published paper, the median event-free survival of the gilteritinib arm was incorrectly presented in Fig. 4. The median value ‘21’ should be presented as ‘2.1’. The original article has been corrected.
